My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}

Want to join the conversation?

$ZTS {{ '2016-06-07T20:40:26+0000' | timeago}} • SEC

$ZTS said in March 2016, $PFE exited its lease of the company's manufacturing site in Guarulhos, Brazil. As of April 1, 2016, the Guarulhos site is owned and operated exclusively by Zoetis for the manufacture of Zoetis's animal health products.

User Mark Collas {{ '2016-10-25T20:12:01+0000' | timeago}}

Waiting with fingers crossed for $AAPL’s fourth quarter earnings.

User RC xNair {{ '2016-10-25T17:04:47+0000' | timeago}}

Looking ahead to $AAPL earnings release later in the afternoon today? Gene Munster, analyst from Piper Jaffrey and the most respected authority for Apple, had this to say - "The second and slightly larger group of investors believe the tail of the iPhone 7 is irrelevant, and is betting that the iPhone 10th Anniversary will yield a jump in growth from flat to up ~15%."

User Carlton Davis {{ '2016-10-24T19:31:20+0000' | timeago}}

$COL agreed to buy $BEAV for $6.4 billion in cash and stock. Also Rockwell Collins reported higher 4Q16 earnings on growth in Government Systems and higher revenue in Information Management Services.

User Charles Elliston {{ '2016-10-24T19:15:21+0000' | timeago}}

Wow! What a buzz the $T-$TWX deal is making! Almost everyone from politicians to competitors have come out against this deal. Even Wall Street doesn’t seem to be too thrilled. Both stocks were down today.

User Vishnu Beri {{ '2016-10-24T17:33:28+0000' | timeago}}

Visa ($V) set to release it earning after market close today. With new CEO resigning so close to the earnings, should we expect to see any surprises? Visa has been making strong moves with Visa Europe acquisition, partnership with PayPal and a 15% increase if quarterly dividends.

$VRTX {{ '2016-10-25T21:09:37+0000' | timeago}} • Webcast

For 2016, $VRTX reiterated the lowered revenue outlook for cystic fibrosis treating drug Orkambi, hurt by U.S. treatment trends and ongoing slower-than-expected launch in Germany. The company will not be able recognize the revenue for patients in France until it achieves a formal reimbursement agreement.

$VRTX {{ '2016-10-25T21:09:33+0000' | timeago}} • Webcast

$VRTX said it continues to expect total 2016 product revenues for ORKAMBI of $950-$990MM. ORKAMBI treats Cystic fibrosis, which is a genetic disorder that affects mostly the lungs. The company also expects total 2016 product revenues for cystic fibrosis drug KALYDECO of $685-$705MM.

$AAPL {{ '2016-10-25T21:08:35+0000' | timeago}} • Announcement

In 4Q16, $AAPL posted iPhone revenues of $28.1Bil, down from $32.2Bil in 4Q15. Revenues from iPad totaled  $4.2Bil and Mac revenues totaled $5.7Bil. Revenues from Services totaled $6.3Bil and revenues from Other Products totaled $2.3Bil.

$AKAM {{ '2016-10-25T21:08:17+0000' | timeago}} • Webcast

Revenue from $AKAM's Services and Support Solutions was $51MM in 3Q16, up 17% year-over-year. The company continues to see strong service attachment rates for its higher-end enterprise class professional services globally.

$AKAM {{ '2016-10-25T21:06:25+0000' | timeago}} • Webcast

$AKAM's Media Delivery Solutions had revenue of $188MM in 3Q16, down 14% year-over-year. The impact of DIY efforts and a few of the company's Internet platform customers continued to weigh heavily on growth rates in this solution category. Excluding the six large Internet platform customers, revenue was up 5% year-over-year.